Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 5/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 3/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL2670938 | 0.86 | KDM4E (0.62) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL3388245 | 0.85 | KDM4E (0.66) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL29831204 | 0.85 | KDM4E (0.66) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL14610232 | 0.82 | PIM1 (0.68) | PIM1KDM4EKMT2APARP1GRM2 | |
| SCHEMBL2670940 | 0.82 | PIM1 (0.47) | PIM1KDM4EKMT2APARP1HTR3A | |
| SCHEMBL3182339 | 0.81 | PIM1 (1.00) | PIM1KDM4EKMT2APARP1PLAU | |
| SCHEMBL13977541 | 0.80 | PIM1 (0.67) | PIM1KDM4EKMT2APARP1MMP2 | |
| SCHEMBL28346452 | 0.80 | PIM1 (0.45) | PIM1KDM4EKMT2APARP1HTR3A | |
| SCHEMBL4819927 | 0.80 | ALDH1A1 (0.46) | PIM1KDM4EKMT2AMMP2 | |
| SCHEMBL27998643 | 0.80 | CNR2 (0.58) | PIM1KDM4EKMT2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121758365-A | Preparation method of 5-difluoro alkyl-8-amino quinoline amide compound | 阜阳师范大学 | 2026-03-31 | — | — | CN | disclosed |
| CN-1659144-B | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG | 2010-09-08 | — | — | CN | disclosed |
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| CN-1659144-A | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-08-24 | — | — | CN | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | PIM1 1159/4885KDM4E 3072/4885KMT2A 3773/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | PIM1 1159/4885KDM4E 3072/4885KMT2A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.